Nature Communications (Apr 2023)

Mini-PCDH15 gene therapy rescues hearing in a mouse model of Usher syndrome type 1F

  • Maryna V. Ivanchenko,
  • Daniel M. Hathaway,
  • Alex J. Klein,
  • Bifeng Pan,
  • Olga Strelkova,
  • Pedro De-la-Torre,
  • Xudong Wu,
  • Cole W. Peters,
  • Eric M. Mulhall,
  • Kevin T. Booth,
  • Corey Goldstein,
  • Joseph Brower,
  • Marcos Sotomayor,
  • Artur A. Indzhykulian,
  • David P. Corey

DOI
https://doi.org/10.1038/s41467-023-38038-y
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 21

Abstract

Read online

Abstract Usher syndrome type 1 F (USH1F), caused by mutations in the protocadherin-15 gene (PCDH15), is characterized by congenital deafness, lack of balance, and progressive blindness. In hair cells, the receptor cells of the inner ear, PCDH15 is a component of tip links, fine filaments which pull open mechanosensory transduction channels. A simple gene addition therapy for USH1F is challenging because the PCDH15 coding sequence is too large for adeno-associated virus (AAV) vectors. We use rational, structure-based design to engineer mini-PCDH15s in which 3–5 of the 11 extracellular cadherin repeats are deleted, but which still bind a partner protein. Some mini-PCDH15s can fit in an AAV. An AAV encoding one of these, injected into the inner ears of mouse models of USH1F, produces a mini-PCDH15 which properly forms tip links, prevents the degeneration of hair cell bundles, and rescues hearing. Mini-PCDH15s may be a useful therapy for the deafness of USH1F.